---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-22-026595"
form_type: "8-K"
ticker: "BLFS"
cik: "0000834365"
company_name: "BIOLIFE SOLUTIONS INC"
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T02:26:18.259434+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioLife Q3 revenue $40.7M (+21% YoY); biopreservation media +50%; tightens FY22 guidance to $160-164M

## Summary
- GAAP net loss of $10.0M ($0.23 loss per share) vs net income of $79K in Q3 2021.
- Adjusted EBITDA turned positive at $1.4M versus negative $2.1M in Q3 2021.
- Cell Processing platform revenue $18.1M (+57% YoY); Freezer/Thaw Systems $15.3M (-13% YoY).
- Cash, equivalents and marketable securities $62.1M; borrowed $20M via term loan in Q3.
- FY2022 revenue guidance narrowed to $160-164M from $160-166M; organic growth expected 37-40%.

## SEC filing metadata
- accession: 0001437749-22-026595
- form_type: 8-K
- ticker: BLFS
- cik: 0000834365
- company_name: BIOLIFE SOLUTIONS INC
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/0001437749-22-026595-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/bioli20221109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-22-026595
- JSON: https://secwatch.observer/filing/0001437749-22-026595.json
- Plain text: https://secwatch.observer/filing/0001437749-22-026595.txt

## Key facts
- Earnings Releases
  BIOLIFE SOLUTIONS INC reported the three and nine months ended September 30, 2022 results: revenue Total revenue for the third quarter of 2022 was $40.7 million. Guidance reaffirmed.
  - Period: the three and nine months ended September 30, 2022
  - Revenue: Total revenue for the third quarter of 2022 was $40.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: On November 9, 2022, BioLife Solutions, Inc. issued a press release announcing financial results and operational highlights for the third quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/834365/000143774922026595/0001437749-22-026595-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.